SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 30th, 2020 • Immune Therapeutics, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 4, 2020, by and between IMMUNE THERAPEUTICS, INC., a Florida corporation, with its address at 2431 Aloma Ave #124, Winter Park, FL 32792 (the “Company”), and GENEVA ROTH REMARK HOLDINGS, INC., a New York corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “Buyer”).
IMMUNE THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • September 25th, 2019 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This EMPLOYMENT AGREEMENT (this “Agreement”), dated __ September 2019 (the “Effective Date”), is by and between Immune Therapeutics, Inc., a Delaware C-corporation (the “Company”) and Michael K. Handley (the “Executive”).
LOAN AGREEMENTLoan Agreement • May 15th, 2018 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
This LOAN AGREEMENT (this “Agreement”), dated January 9, 2018 (the “Effective Date”), is entered into by and between Immune Therapeutics, Inc., a Florida corporation (“Borrower”), and Joel Yanowitz (‘‘Lender”).
PROMISSORY NOTE SETTLEMENT AGREEMENTPromissory Note Settlement Agreement • March 31st, 2015 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
THIS PROMISSORY NOTE SETTLEMENT AGREEMENT (this “Agreement”) is entered into as of September 26, 2014, by and between TNI BioTech, Inc., a Florida corporation (the “Company”), and Robert Dailey (the “Holder”).
Supplementary Agreement on New Drug Methionine-Enkephalin CooperationSupplementary Cooperation Agreement • August 13th, 2014 • Tni Biotech, Inc. • Pharmaceutical preparations
In October, 2012, Hubei Qianjiang Pharmaceutical Co., Ltd (a Chinese listed company) and TNI Biotech, Inc. (an American company) signed Cooperation Agreement on New Drug Methionine Enkephalin in Qianjiang, Hubei Province, China.
DISTRIBUTION AGREEMENTDistribution Agreement • October 2nd, 2013 • Tni Biotech, Inc. • Pharmaceutical preparations • New York
This Distribution Agreement (“Agreement”), effective as of this 17th day of September, 2013 (the “Effective Date”), is made by and between TNI BioTech International, Ltd. (“Company”), a company duly incorporated and existing under the laws of British Virgin Islands, having an office at Drake Chambers, P.O. Box 3321, Road Town, Tortola, British Virgin Islands, and AHAR Pharma, a company duly incorporated and existing under the laws of Nigeria (“Distributor”), having a registered office at Plot 12A, Olaitan Senbanjo Street, Lekki Phase 1, Lagos, Nigeria.
CONTRACT FOR THE MANUFACTURING OF PHARMACEUTICAL PRODUCTSContract for the Manufacturing of Pharmaceutical Products • August 23rd, 2013 • Tni Biotech, Inc. • Pharmaceutical preparations
The parties hereby agree to enter Contract for the Manufacturing of Pharmaceutical Products, according to the following clauses:
AMENDMENT TO THE SECOND AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • May 14th, 2020 • Immune Therapeutics, Inc. • Pharmaceutical preparations
This amendment (“Third Amendment”) to the Second Amendment to The License Agreement is effective December 31, 2018 (“Effective Date”) by and between Cytocom Inc., a for profit corporation duly organized and existing under the laws of the Commonwealth of Delaware, having an office at 3001 Aloma Ave, Winter Park, FL 32792 (“CYTO”), and Immune Therapeutics Inc., a Florida Corporation, having an office at 2431 Aloma Ave #124 Winter Park, FL 32792 (“IMUN and or Company or Licensee”). CYTO and Licensee may each be referred to individually as “Party” and collectively as “Parties”.
CONTRACT FOR THE COMPOUNDING OF PHARMACEUTICAL PRODUCTSContract for the Compounding of Pharmaceutical Products • May 20th, 2016 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
This CONTRACT FOR THE COMPOUNDING OF PHARMACEUTICAL PRODUCTS (this “Agreement”) is hereby entered into this 16th day of May, 2016, by and between Immune Therapeutics, Inc., a corporation organized and currently existing in good standing under the laws of the State of Florida (“IMUN”), and Complete Pharmacy and Medical Solutions, LLC, a limited liability company also known as Complete Pharmaceutics and organized and currently existing in good standing under the laws of the State of Florida (“CPMS”). IMUN and CPMS are sometimes hereinafter referred to individually as a “party” and/or collectively as the “parties”.
DEFINITIVE AGREEMENTIntellectual Property License Agreement • October 12th, 2022 • Immune Therapeutics, Inc. • Pharmaceutical preparations
THIS INTELLECTUAL PROPERTY LICENSE AGREEMENT (the “Agreement”), effective September 30, 2022 (the “Effective Date”), is entered into by Immune Therapeutics, Inc., a corporation duly organized and existing under the laws of the state of Florida, having a principal place of business at 2431 Aloma Ave, Winter Park, Florida (herein referred to as IMUN or “Licensee”), and TaiwanJ Pharmaceuticals a Taiwan corporation having a principal place of business 3F-4, No6-1 Sec2 ShenYi Rd, Chubei, Hsinchu, Taiwan (herein referred to as “TPEX” or “Licensor”). IMUN and TPEX are sometimes hereinafter referred to as a party (collectively “Parties”) to this Agreement.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • June 11th, 2018 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
This STOCK Purchase Agreement (this “Agreement”) is made and entered into effective as of the 4th day of June 2018, by and between Immune Therapeutics, Inc., a Florida corporation (“IMUN”), and Cytocom, Inc., a Delaware corporation (“Company”).
ROYALTY AGREEMENTRoyalty Agreement • May 21st, 2015 • Immune Therapeutics, Inc. • Pharmaceutical preparations
THIS ROYALTY AGREEMENT (this “Agreement”) is entered into and effective as of May 15, 2015, by and between Immune Therapeutics, Inc., a Florida corporation formerly known as TNI BioTech, Inc. (the “Company”), and Chris Pearce, individually (“Pearce”).
EXECUTION COPY Patent License AgreementPatent License Agreement • June 7th, 2013 • Tni Biotech, Inc. • Pharmaceutical preparations • New York
This Patent License Agreement (this “Agreement”) is between Dr. Jill P. Smith and LDN Research Group LLC (the “Licensor Parties”), and TNI BioTech, Inc., a publicly traded corporation organized and existing under the laws of Florida (“Company”). This Agreement is being signed on 18th December 2012 (the “Execution Date”). This Agreement will become effective on December 18t, 2012 (the “Effective Date”). The Company and the Licensor Parties may be referred to collectively as the “parties” and singularly as a “party.”
SERVICES AGREEMENTServices Agreement • March 31st, 2015 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
This Services Agreement (this "Agreement") is made and entered into as of the 15th day of December 2014 by and between Aronstam Management Services Inc., a Florida corporation represented by its President Peter Aronstam (“Contractor"), and Immune Therapeutics, Inc., a Florida corporation formerly known as TNI BioTech, Inc. (the "Company''), who are hereinafter sometimes collectively referred to as "the parties."
IMMUNE THERAPEUTICS & FORTE BIOTECHNOLOGY INTL CORP LICENSE AGREEMENTLicense Agreement • May 14th, 2020 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
Agreement: Immune Therapeutics, Inc. (“Immune” or “IMUN” or “Licensor”) owns or otherwise controls intellectual property relating to the proprietary therapeutic composition known as “Low Dose Naltrexone” or “Lodonal” or “LDN” and also owns or otherwise controls to the composition known as Methionine Enkephalin or MENK. Immune is willing to grant to Forte Biotechnology Intl. Corp (“Forte” or “FBIC” or “Licensee”) an exclusive license to develop and commercialize pharmaceutical products consisting of Lodonal and MENK for use in veterinary applications for all indications world-wide.
CONTRACT FOR THE MANUFACTURING OF PHARMACEUTICAL PRODUCTSManufacturing Agreement • November 15th, 2016 • Immune Therapeutics, Inc. • Pharmaceutical preparations
Immune Therapeutics, Inc. registered under the laws of the State of Florida, United States of America, and incorporated under P3000082736Twrth its corporate domicile and main office at 37 N Orange Ave 607, Orlando Florida and represented by Noreen Griffin, Chief Executive Officer, with her Passport No.496803653.
Immune Therapeutics, Inc. Short-Form Employment AgreementShort-Form Employment Agreement • July 27th, 2020 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
This Employment Agreement (this “Agreement”) is made effective as of April 29, 2020, by and between Immune Therapeutics, Inc. (“Immune”), a Florida Corporation, and Kevin J. Phelps (“Executive”), of Rochester, New York.
PRC AMENDMENT TO THE SECOND AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • May 14th, 2020 • Immune Therapeutics, Inc. • Pharmaceutical preparations
This amendment to the Second Amendment to The License Agreement (herein referred to as the “PRC Amendment”) is effective December 31, 2018 (“Effective Date”) by and between Cytocom, Inc., a for profit corporation duly organized and existing under the laws of the Commonwealth of Delaware, having an office at 3001 Aloma Ave, Winter Park, FL 32792 (“CYTO”), and Immune Therapeutics, Inc., a Florida Corporation, having an office at 2431 Aloma Ave #124 Winter Park, FL 32792 (“IMUN and or Company or Licensee”). CYTO and Licensee may each be referred to individually as “Party” and collectively as “Parties”.
SECOND AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 20th, 2019 • Immune Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to License Agreement (“Second Amendment”) is effective December 31, 2018 (“Effective Date”), by and between: Cytocom Inc., a for profit corporation duly organized and existing under the laws of the Commonwealth of Delaware, having an office at 37 North Orange Ave Suite 607 Orlando Florida 32801 (“CYTO”), and Immune Therapeutics Inc., a Florida Corporation formerly doing business as TNI BioTech, Inc., having an office at 2431 Aloma Ave #124 Winter Park, FL 32792 (“IMUN and or Company or Licensee”). CYTO and Licensee may each be referred to individually as “Party” and collectively as “Parties”.
EMPLOYMENT AGREEMENTEmployment Agreement • August 15th, 2016 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into on May 1, 2016 by and between Immune Therapeutics, Inc., a Florida corporation (“IMUN”), and Robert Wilson (“Employee”), currently residing at 1727 Lake Berry Drive, Winter Park, Florida 32789.
PATENT LICENSE AGREEMENTPatent License Agreement • June 7th, 2013 • Tni Biotech, Inc. • Pharmaceutical preparations • Pennsylvania
This Patent License Agreement (this “Agreement”) is between The Penn State Research Foundation, a Pennsylvania nonprofit corporation (“PSRF”), and TNI BioTech, Inc., a publicly traded corporation organized and existing under the laws of Florida (“Company”). This Agreement will become effective on the date of last signature (the “Effective Date”).
Patent License AgreementPatent License Agreement • January 23rd, 2014 • Tni Biotech, Inc. • Pharmaceutical preparations • Pennsylvania
This Patent License Agreement (this “Agreement”) is between The Penn State Research Foundation, a Pennsylvania nonprofit corporation (“PSRF”), and TNI BioTech, Inc., a publicly traded corporation organized and existing under the laws of Florida (“Company”). This Agreement will become effective on the date of last signature (the “Effective Date”).
Patent License AgreementPatent License Agreement • January 23rd, 2014 • Tni Biotech, Inc. • Pharmaceutical preparations • New York
This Patent License Agreement (this “Agreement”) is between Dr. Jill P. Smith and LDN Research Group LLC (the “Licensor Parties”), and TNI BioTech, Inc., a publicly traded corporation organized and existing under the laws of Florida (“Company”). This Agreement is being signed on 24th December 2012 (the “Execution Date”). This Agreement will become effective on December 24th, 2012 (the “Effective Date”). The Company and the Licensor Parties may be referred to collectively as the “parties” and singularly as a “party.”
June 30, 2016Services Agreement • November 10th, 2016 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
EXCLUSIVE AGENCY AGREEMENTExclusive Agency Agreement • November 15th, 2016 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
This EXCLUSIVE AGENCY AGREEMENT is made and entered into this 31st day of October, 2016 by and among Immune Therapeutics, Inc., a Florida corporation (“IMUN”), its wholly owned subsidiary, TNI BioTech International, Ltd., a BVI company (collectively with IMUN, the “Company”), and GB Pharma Holdings, LLC, a Delaware limited liability company (“Agent”). The Company and Agent are each referred to herein as a “Party” and collectively as the “Parties.”
CONTRACT FOR THE COMPOUNDING OF PHARMACEUTICAL PRODUCTSContract for the Compounding of Pharmaceutical Products • December 15th, 2014 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
This CONTRACT FOR THE COMPOUNDING OF PHARMACEUTICAL PRODUCTS (this “Agreement”) is hereby entered into this 8th day of December, 2014, by and between Immune Therapeutics, Inc., a company organized and currently existing in good standing under the laws of the State of Florida and formerly known as TNI BioTech, Inc. (“TNI”); and KRS Global Bio Technology, Inc., a company organized and currently existing in good standing under the laws of the State of Florida (“KRS”). TNI and KRS are sometimes hereinafter referred to individually as a “party” and/or collectively as the “parties”.
Via Electronic Mail TNI BioTech, Inc.Engagement Agreement for Corporate Advisory Services • September 25th, 2013 • Tni Biotech, Inc. • Pharmaceutical preparations
LICENSE AGREEMENTLicense Agreement • June 11th, 2018 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
This LICENSE AGREEMENT (the “Agreement”) is made as of May 1, 2018 (the “Effective Date”) by and between Cytocom Inc., a Delaware corporation having its principal place of business at 37 North Orange Ave Suite 607 Orlando Florida 32801 United States (“Cytocom”), and Immune Therapeutics Inc., a company registered under the laws of Florida, and having a registered office at 37 North Orange Ave Suite 607 Orlando Florida 32801 (“Licensee”). This Agreement amends and restates in its entirety the license agreement between the parties, dated September 30, 2014.
DISTRIBUTION AGREEMENTDistribution Agreement • March 31st, 2014 • Tni Biotech, Inc. • Pharmaceutical preparations • New York
This Distribution Agreement (“Agreement”), effective as of this 17th day of September, 2013 (the “Effective Date”), is made by and between TNI BioTech International, Ltd. (“Company”), a company duly incorporated and existing under the laws of British Virgin Islands, having an office at Drake Chambers, P.O. Box 3321, Road Town, Tortola, British Virgin Islands, and AHAR Pharma, a company duly incorporated and existing under the laws of Nigeria (“Distributor”), having a registered office at Plot 12A, Olaitan Senbanjo Street, Lekki Phase 1, Lagos, Nigeria.
DISTRIBUTION AGREEMENTDistribution Agreement • June 25th, 2014 • Tni Biotech, Inc. • Pharmaceutical preparations • New York
This Distribution Agreement (“Agreement”), effective as of this 11th day of June 2014 (the “Effective Date”), is made by and between Airmed Biopharma Limited, a company duly incorporated in Ireland and existing under the laws of Ireland (“Company”) with an address at c/o Shane Hogan, Matheson, 70 Sir John Rogerson’s Quay, Dublin 2, and PanAm Global Logistics, Inc., a company duly incorporated in Panama and existing under the laws of Panama (“Distributor”), with an address at Costa del Este, Edificio Top Tower, Piso 9, Unidad 1, Panama, Republica de Panama.
MUTUAL RELEASE AND NON-DISPARAGEMENT AGREEMENT [Immune Therapeutics, Inc. and Mr. Michael K. Handley]Mutual Release and Non-Disparagement Agreement • May 5th, 2020 • Immune Therapeutics, Inc. • Pharmaceutical preparations • Florida
This Mutual Release and Non-Disparagement Agreement (the “Agreement”) is entered into on April 26, 2020, by and between Michael K. Handley (“Mr. Handley”), a resident of the State of Colorado, and Immune Therapeutics, Inc. (the “Company”), a Florida Corporation.
CONSULTING AGREEMENTConsulting Agreement • March 31st, 2015 • Immune Therapeutics, Inc. • Pharmaceutical preparations • New York
The Sevin Group LLC, a New York Limited Liability Company, existing and organized under the laws of New York State, having its registered head office at 66 West 38th Street, Suite 16D, New York, NY 10018, (hereinafter referred to as “SeVin”),
